There is a hypothesis that behavioral problems in children with pervasive developmental disorder are highly associated with the neurotransmitter imbalances. Therefore, psychotropic medications (eg. atypical antipsychotics, selective serotonin reuptake inhibitors, and psychostimulants), which work on dopamine and serotonin receptors, are the FDA- 4 On the other hands, treatments associated with the neurotransmitters more common.
therapy was first reported to improve speech and participants showed improvement in speech and language. 4 Since then, the study of vitamin B6 use for some clinicians administered it empirically, but none has been able to produce a conclusive result. It was found that in autistic children the enzyme 5 neurotransmitters serotonin, dopamine, gamma aminobutyric acid (GABA), and the catecholamines. 6, 7 effects on human metabolism, including those on as a therapy is implausible as the phosphate group is no additional benefit. 6 Ames et al then postulated 7 of vitamin B6 increased intracellular substrate concentrations and thus activated the defective enzymes to phosphorylate 8 In our center, vitamin B6 is often empirically prescribed in low-dose (not in accordance with standard operational procedure), although no prior assessment to its efficacy ever studied before. Hence this review is conducted to increase the awareness of and to superior to placebo as a therapeutic management in
Case illustration
A 7-year old boy with autistic specturm disorder accompanied by her mother came for a routine control Two years ago, his mother realized that he could not behave calmly, frequently got temper tantrum, and easily got upset and uneasy. He also could not communicate verbally or non-verbally. The was no significant eye contact, and he did not follow simple without any meanings. However, there was not any self-destructive behavior nor any attempt to harm other people. He was taken to hospital to have speech and occupational therapy.
Two months ago, a therapist told his mother that the patient is diagnosed as autistic spectrum disorder and could not be helped only with the speech and occupational therapy only. He also needed a medication for reducing his autistic behavior.
needs by using a non-verbal behavior. Although he is getting better at maintaining his eye contact, but he is still reported to have few friends at his school, have no social reciprocity and lack of social repetitive, or idiosyncratic language. He did not show any response when another child asked him to play room, and even climbed up the chair. According to his mother, he likes to flap his fingers every time he
Methods
The The Cochrane, EMBASE, PubMed, PsycINFO B6 and placebo in improving social, communication,
collected.
Searches were limited to randomized controlled trials (RCTs), systematic review, or meta-analysis as is not written in English or Indonesian language. The flowchart of searching and selection strategy can be seen in Figure 1 .
Results
A total of 35 studies were retrived after screening potential inclusion, of which 7 studies remained after in a systematic review, only 3 studies included into this review.
No meta-analysis is identified. Cochrane Review reported only 3 out of 85 studies met the inclusion criteria are relevant to the study. it is impossible to produce a meta-analysis due to and differences in both clinical populations and outcome measures between another two remaining ).
to produce a systematic review which concluded a finding that current studies are unable to provide sufficient data to warrant the effectiveness and This
An updated systematic review is conducted by who reviewed one study by Adams 5 therapy, but instead a moderate dose of multivitamin and mineral supplement. Hence, result of the study might be erroneously interpreted. Considering the shortcomings of the study, Murza et al concluded they
Critical appraisal of Tolbert et al. 10 We assessed the Tolbert et al. study as valid. They described and randomized their treatment assignments no details of the randomizing process were given in their report. Characteristics of participants in the were followed up for a sufficient duration and completely (35 weeks), analyzed in the groups to which they belonged, and were treated similarly, and clinicians were blinded to treatment.
article could not be assessed, as the data was relative risk (ARR), relative risk reduction (RRR), and number needed to treat (NNT). 8 Nor did the authors use pooled SD and effect size. Applicability analysis of this article revealed that it could not be applied to our patient, despite the similarity of the study sample characteristics to our patient's condition and the clinical question asked. Additionally, Tolbert et al. reported no benefit and no harm from administering Values and preferences of the patient were not assessed. Hence, applicability to our patient remains questionable.
Critical appraisal of Findling et al. 11
Findling et al treatment assignment (control group and vitamin of their randomization process. Characteristics of participants were not significantly different between groups. Two participants withdrew from the study. to which they belonged, and were treated similarly, and clinicians were blinded to treatment. Applicability analysis of this article revealed that it could be applied to our patient, however, no beneficial effect was shown in the study. The study sample characteristics were similar to that of our patient and they asked similar clinical questions. However, the study reported no beneficial effect bsed on the performance scales assessed as well as mild adverse effects of treatment. As such, there was no clear indication for us to start treating our patient with the combination. Additionally, patient's value and preferences had not yet been assessed.
Critical appraisal of Kuriyama et al. 12
et al groups). However, they did not report the details of their randomization process. Characteristics of participants were not significantly different between term (4 weeks), analyzed in the groups to which they were blinded to treatment. assessed using the Critical Appraisal Worksheet from Dartmouth College: Therapy study with continuous outcome calculations.
et al report the details on their research, however, an intervention review by Nye et al. 7 et al. The study showed no significant results for total IQ, verbal IQ, performance showed no significant beneficial effect on IQ or SQ compared to placebo.
Applicability analysis of this article revealed that it could not be applied to our patient as it did not match his characteristics, was not feasible, and the values and preferences of the patient had not yet been assessed.
Discussion
Autism enzyme or enzymes involved in the metabolism of serotonin and dopamine, although a genetic link established yet. 8 Most commonly clinical sign of autism is an elevation of whole-blood serotonin patients. Increased concentrations of homovanillic acid, a breakdown product of dopamine, have also been found in several autistic patients. successful in autism, 7 requiring enzyme might be defective in those patients enzyme directly involved with the synthesis or degradation of dopamine and serotonin is AADC 8 However, elevated homovanillic acid, which is at least partially in this enzyme. 8 Additionally, cases of AADC deficiency have been reported in the literature and result only in a very severe inborn metabolic disorder involving deficient concentrations of dopamine and serotonin. 8 It remains to be a question whether other enzymes in the metabolic pathways of these neurotransmitters may be responsible for the various forms of autism that involve altered neurotransmitter NAD, S-adenosylmethionine, tetrahydrobiopterin, and ascorbate are also used by enzymes in serotonin and dopamine metabolism. 8 Therefore, it is hypothesized if different autistic patients harbor mutations in different metabolic enzymes, it may be possible to reverse the effects of autism by targeting a treatment to each individual patient. However, what should be taken into consideration is autism is diagnosed so little is known about the biochemical basis of this condition, hence it is difficult to associate a treatment response with a particular biochemical or physiologic pathway. 8 treatment of autism remains as a challenge due to methodological shortcomings inherent in the studies. 7 and Murza et al consistently stated that vitamin B6 may not be effective in improving clinical manifestations of autism in comparison with placebo. Although vitamin B6 is relatively safe to administer due to its water-solubility characteristic, however possible adverse effects as a result of highdose vitamin B6 and magnesium should be taken into account when prescribing vitamin B6 in patients of vitamin B6 is associated with dorsal root ganglia impairment, painful and neurological problems, peripheral neuropathy (eg. numbness or tingling, weakness, feelings of burning, tickling, or pricking in breathing difficulties, fatigue, and vomiting.
Another adverse effects, which are commonly reported are enuresis, irritability, and sensitivity to sound. lessened some of the adverse effects when only Rossignol et al magnesium as grade C treatment in their review. They for autism spectrum disorders as follows: therapy; and cyroheptadine, famotidine, glutamate antagonists, acupuncture, auditory integration training, massage, and neurofeedback. systematic review conducted by Rossignol et al , and availability, feasibility, and cost-effectiveness of the supplementations reviewed, vitamin C may be a better et al carried out a randomized double-blinded placebosignificant improvements in stereotypical behaviors, including rocking, pacing, and whirling without any adverse effect were noted. No study is found regarding the drug interaction between vitamin B6 and vitamin C with risperidone, as the FDA-approved medication
In conclusion, there is insufficient evidence to warrant the advocacy of vitamin B6 whether in monotherapy or in combination with magnesium as therapeutic approach to improve individuals with ocial, communication, and behavioral responses) when compared to placebo. Furthermore, administration of high-dose vitamin B6 may lead to several adverse effects. .
